Pharmaceuticals

MYL released FY2025 Annual Earnings on April 24 After-Market (BJT), Actual Revenue: CNY 3.867 B (Forecast: CNY 4.325 B), Actual EPS: CNY 1.35 (Forecast: CNY 1.515)

MYL released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 1.029 B, actual EPS CNY 0.1883

MYL released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 1.012 B, actual EPS CNY 0.49

MYL to release FY2025 earnings report on April 25 After-Market (BJT), forecast revenue CNY 4.325 B, EPS CNY 1.515

MYL FY2026 Q1 Earnings Release on April 25 Pre-Market BJT

MYL released FY2025 9 Months Earnings on October 29 Pre-Market (BJT), actual revenue CNY 2.837 B, actual EPS CNY 1.1591

MYL released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 888.26 M, actual EPS CNY 0.3605

MYL FY2025 Q3 Earnings Release on October 30, 2025 Pre-Market BJT

MYL released FY2025 Semi-Annual earnings on August 28 After-Market (BJT), actual revenue CNY 1.949 B, actual EPS CNY 0.8

MYL released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 979.88 M, actual EPS CNY 0.3286

MYL FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Maydragon Meikang Obtains Hyaluronic Acid Eye Drops Drug Registration Certificate

Mayinglong Adds Ophthalmology Concept

China Merchants Securities resumes tracking and rates MAPLE LEAF BUY

Ma'yinglong reports 2.99% YoY increase in Q1 net profit

MYL released FY2025 Q1 earnings on April 25 After-Market (BJT), actual revenue CNY 969.15 M, actual EPS CNY 0.47

MYL to Release FY2025 Q1 Earnings Report on April 26 After-Market BJT

Dongwu Securities Releases Mayinglong 2024 Annual Report Review, Assigns Buy Rating

MYL released FY2024 Q4 earnings on April 2 After-Market BJT, actual revenue CNY 936.21 M, actual EPS CNY 0.167

MYL released FY2024 Annual Earnings on April 2 After-Market (BJT), Actual Revenue: CNY 3.728 B (Forecast: CNY 3.7 B), Actual EPS: CNY 1.23 (Forecast: CNY 1.3033)

The bleeding disorder testing market is projected to grow from USD 109.2 billion in 2025 to USD 234.6 billion by 2036, with a CAGR of 7.2%. This growth is driven by rising demand for performance-grade diagnostic solutions, increased hospital procurement, and a focus on regulatory compliance. Key segments include reagents and consumables, with hemophilia A being the leading indication. Major growth regions include China, India, Germany, France, and the United States, as healthcare institutions prioritize reliable diagnostic systems.

MorningStar

Siemens Healthineers AG

Roche

Thermo Fisher Scentific

Abbott Laboratories

Horiba , Ltd.

Pfizer

Baxter

ROCHE HOLDINGS AG

FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

600993

MYL announced that its subsidiary Jiangxi MYL Meikang Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops issued by the National Medical Products Administration. Olopatadine Hydrochloride Eye Drops are used to treat eye itching associated with allergic conjunctivitis

Zhitong

MYL: Subsidiary obtains drug registration certificate

603233

688621

688161

688185

06185

601567

Bank of China International released a research report stating that the Medical Insurance Bureau has launched the 11th batch of centralized procurement, emphasizing the principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and resisting involution," while optimizing procurement rules. This centralized procurement will no longer simply reference the lowest price; companies with the lowest bids are required to publicly explain the rationale and commit to not quoting below cost. It is expected that as price expectations stabilize, the profitability of the pharmaceutical industry will gradually improve, and it is recommended to pay attention to the revaluation opportunities in the pharmaceutical sector

Sun-Novo

Wego Ortho

CanSinoBIO

CANSINOBIO

SANXING

Bank of China International: The Medical Insurance Bureau clarifies that centralized procurement is against involution, focusing on re-evaluation opportunities in the pharmaceutical sector

MYL's wholly-owned subsidiary, Jiangxi MYL Meikang Pharmaceutical Co., Ltd., recently obtained the sodium hyaluronate eye drops drug registration certificate issued by the National Medical Products Administration. This approval will enrich the company's ophthalmic product line and enhance market competitiveness

MYL's subsidiary obtains drug registration certificate for sodium hyaluronate eye drops

CITIC Securities: Resuming coverage of MYL, rating Buy

CMSC

According to the Zhitong Finance APP, MYL disclosed its first-quarter report for 2025, showing that the company achieved revenue of 969 million yuan during the reporting period, a year-on-year increase of 1.48%; net profit attributable to shareholders was 204 million yuan, a year-on-year increase of 2.99%; and net profit excluding non-recurring items was 195 million yuan, a year-on-year increase of 1.01%. The basic earnings per share were 0.47 yuan

MYL released its first-quarter performance, with a net profit attributable to the parent company of 204 million yuan, a year-on-year increase of 2.99%

MYL released its 2024 annual performance, with operating revenue of 3.728 billion yuan, a year-on-year increase of 18.85%; net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%; net profit excluding non-recurring gains and losses of 511 million yuan, a year-on-year increase of 44.98%; basic earnings per share of 1.23 yuan/share. It plans to distribute a cash dividend of 6.20 yuan for every 10 shares. The main business revenue of the pharmaceutical industry, medical services, and pharmaceutical commerce increased by 17.82%, 30.15%, and 14.81% year-on-year, respectively

MYL released its 2024 annual performance, with a net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%

After the CCTV investigation report "Uncovering the Sales Network Behind 'Medical Insurance Cash Withdrawal' and 'Reflow Drugs'" was broadcast, the Sichuan Provincial Health and Health Commission immediately instructed the health departments at the municipal and district levels in Chengdu to coordinate with relevant departments such as medical insurance, market supervision, and drug supervision to conduct an in-depth investigation into the matter, handle it seriously according to laws and regulations, and resolutely safeguard the interests of the public. The Wuhan Medical Insurance Bureau, Market Supervision Administration, and Public Security Bureau in Hubei Province formed a joint investigation team to investigate the involved pharmacies, and the medical insurance settlement for three pharmacies, including MYL, has been suspended

Sichuan and Hubei have launched a joint investigation into "reflow drugs," and 3 pharmacies have suspended medical insurance settlements

MYL(600993.SH)